SCYNEXIS (SCYX) M&A announcement summary

Deal rationale and strategic fit

• Acquisition of global rights to SCY-770, a direct and novel AMPK activator, marks a strategic shift to rare renal diseases, targeting ADPKD and leveraging expertise in orphan and severe disease drug development.

• SCY-770 offers a differentiated mechanism of action, robust preclinical and clinical data, and potential for improved efficacy and safety over current therapies.

• The asset addresses a significant unmet need in ADPKD, with potential expansion to other indications and strong commercial prospects.

• The acquisition aligns with a focus on severe rare diseases and is supported by a strategic review aimed at pipeline expansion and shareholder value creation.

• The move positions the company as a leader in rare disease therapeutics, building on a proven development track record.

Financial terms and conditions

• Upfront payment of $8 million to Poxel for global rights to SCY-770, with up to $8 million in development milestones.

• Up to $180 million in commercial milestones, including $125 million triggered by annual net sales exceeding $1 billion.

• No royalties owed on future sales.

• Recent PIPE financing and acquisition extend cash runway to mid-2029, supporting completion of phase II for SCY-770.

• Excludes potential milestone and royalty receipts from partnered antifungal assets.

Synergies and expected cost savings

• Acquisition leverages existing development expertise and resources to efficiently advance SCY-770.

• Existing antifungal portfolio positioned for non-dilutive funding or partnering, supporting overall financial flexibility.

• $40 million PIPE financing completed, providing flexibility for strategic initiatives.